The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Johnson & Johnson (NYSE:JNJ) is one of the best stocks to buy according to Goldman Sachs’ Conviction List. Goldman added Johnson & Johnson to its U.S. May Directors’ Cut Conviction List on May 1, 2025, alongside Houlihan Lokey, while removing Meritage Homes. The update described the list as a curated selection of stocks Goldman believes hold strong investment potential, though inclusion is separate from a formal rating change. The company’s latest results support the defensive-growth case without needing any heroic spreadsheet acrobatics. On April 14, Johnson & Johnson reported Q1 2026 sales of $24.1 billion, up 9.9% year-over-year, with operational sales growth of 6.4%. Adjusted EPS came in at $2.70, and the company raised its 2026 outlook to estimated reported sales of $100.8 billion and adjusted EPS of $11.55 at the midpoint. Innovative Medicine sales rose 11.2% to $15.43 billion, while MedTech sales increased 7.7% to $8.64 billion.

Trong Nguyen / Shutterstock.com The pipeline also remains active. Johnson & Johnson highlighted recent approvals for ICOTYDE in plaque psoriasis, TECVAYLI plus DARZALEX FASPRO in multiple myeloma, VARIPULSE Pro in Europe, and TECNIS PureSee for U.S. cataract patients. On May 5, it also reported Phase 2b DUET data for JNJ-4804 in inflammatory bowel disease and pivotal study results for its investigational OTTAVA soft-tissue surgical robotic system. Johnson & Johnson (NYSE:JNJ) is a healthcare company focused on Innovative Medicine and medical technology, with products and therapies across oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopedics, surgery, and vision. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.  Disclosure: None. Follow Insider Monkey on Google News.